Hualan Biological Engineering: 2025 revenue rose 4.93% to ¥4.60B, net profit fell 13.55% to ¥940M, dividend payout 97%

About this update from Hualan Biological Engineering Inc. Class A

Revenue grew 4.93% to ¥4.60 billion, with net profit down 13.55% to ¥940 million. Blood products and vaccines both saw revenue growth, while R&D investment increased and a high dividend payout was maintained.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Hualan Biological Engineering Inc. Class A